FDA to hold hearing on new interchangeable insulin policy

FDA will hold a public hearing May 13 to seek comments on its plan to transition regulation of insulin products to the BLA pathway. While the change will afford

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE